Acarbose (Glucobay, BAYG5421)
DrugPatients with diabetes type 2 newly treated with Glucobay
NCT Number: NCT00909051
Evaluation of safety and effectiveness of Glucobay® under daily-life treatment conditions in a large sample of patients.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Multiple Locations, Algeria
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients with diabetes type 2 newly treated with Glucobay
Time frame: During observation period of three months
Bayer
Industry
Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04083456
Amputation, Arterial Occlusive Diseases
Aurora, Colorado, United States
View Trial DetailsNCT05435157
Diabetes Mellitus, Endocrine System Diseases
Salamanca, Spain
View Trial DetailsNCT01934660
Cardiovascular Disease, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT04040634
Cardiovascular Diseases, Cognition Disorders
Maceió, Alagoas, Brazil
View Trial Details